Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Panminerva Med ; 53(3 Suppl 1): 83-7, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22108482

RESUMO

AIM: The aim of this study was to test mf Odondovis Calcium® as a food supplement in a 3-month product evaluation study measuring how the low jaw bone density, could be improved. The upper jaw density was tested with an ultrasound method, evaluating the grey scale median of the images (GSM). METHODS: Seventy nine subjects were enrolled; 22 normal subjects (group A) and 57 with upper jaw osteoporosis (according to DEXA values). Patients were divided into 2 groups (group B and C, respectively 28 and 29 cases). These subjects were treated with what was considered the' best treatment' and in the group B only was added mf Odontovis Calcium®, consisting of calcium salts, Vitamin D and physiological modulators with antioxidant activity. This treatment continued for 3 months. RESULTS: The GSM of osteoporotic patients was significantly lower in comparison with GSM in normal subjects. No changes were observed (between the inclusion and 3 month values) in normal subjects and minimal, non-significant changes were observed in control osteoporosis patients. Before-after treatment values of GSM in treatment patients showed a significant increase (P<0.022) at 3 months. The increase in GSM in these patients was significantly higher (P<0.05) in comparison with control patient with osteoporosis. The Tolerability of the product was very good and the compliance corresponded to 98%. CONCLUSION: the jaw density in patients with osteoporosis is increased in only 3 months with supplementation with mf Odontovis Calcium®. Long-term clinical implications should be observed in more prolonged studies.


Assuntos
Antioxidantes/administração & dosagem , Cálcio da Dieta/administração & dosagem , Doenças Maxilomandibulares/tratamento farmacológico , Osteoporose/tratamento farmacológico , Vitamina D/administração & dosagem , Adulto , Densidade Óssea/efeitos dos fármacos , Carotenoides/administração & dosagem , Suplementos Nutricionais , Feminino , Flavonoides/administração & dosagem , Humanos , Doenças Maxilomandibulares/diagnóstico por imagem , Doenças Maxilomandibulares/metabolismo , Licopeno , Masculino , Pessoa de Meia-Idade , Osteoporose/diagnóstico por imagem , Osteoporose/metabolismo , Ultrassonografia , Xantofilas/administração & dosagem
2.
Patol Fiziol Eksp Ter ; (4): 20-2, 1998.
Artigo em Russo | MEDLINE | ID: mdl-9951297

RESUMO

Urea levels were measured in the saliva of 30 patients with acute and chronic maxillofacial inflammation treated with multiple modalities including hyperbaric oxygenation (HBO). Urea concentrations were evaluated before, in the course of and after HBO session. A total of four 40-min sessions were made (1 session a day, 1.5 atm). Elevated concentrations of urea after HBO are thought adaptive, serving for elimination of ammonia overproduction in hyperoxia. Urea measurements in the saliva can be used for prediction of oxygen intoxication in the HBO-exposed patients.


Assuntos
Celulite (Flegmão)/terapia , Oxigenoterapia Hiperbárica , Doenças Maxilomandibulares/terapia , Saliva/química , Ureia/análise , Doença Aguda , Adulto , Celulite (Flegmão)/metabolismo , Doença Crônica , Terapia Combinada , Face , Feminino , Humanos , Inflamação/metabolismo , Inflamação/terapia , Doenças Maxilomandibulares/metabolismo , Masculino , Prognóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA